Research Paper Volume 16, Issue 1 pp 948—963
Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer
Figure 3. Forest plots of (A) hazard ratios for overall survival, and (B) risk ratios for objective response in gastric cancer patients treated with immunotherapy. Chem, chemotherapy; ICI, immune checkpoint inhibitor; Ipi, ipilimumab; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; Niv, nivolumab; Pem, pembrolizumab.